Is Enlivex Therapeutics Stock a Good Investment?
Enlivex Therapeutics Investment Advice | ENLV |
- Examine Enlivex Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Enlivex Therapeutics' leadership team and their track record. Good management can help Enlivex Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Application Software space and any emerging trends that could impact Enlivex Therapeutics' business and its evolving consumer preferences.
- Compare Enlivex Therapeutics' performance and market position to its competitors. Analyze how Enlivex Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Enlivex Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Enlivex Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Enlivex Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Enlivex Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Enlivex Therapeutics Stock
Researching Enlivex Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 22.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.87. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enlivex Therapeutics recorded a loss per share of 0.98. The entity last dividend was issued on the 6th of March 2019. The firm had 1:8 split on the 6th of March 2019.
To determine if Enlivex Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Enlivex Therapeutics' research are outlined below:
| Enlivex Therapeutics generated a negative expected return over the last 90 days | |
| Enlivex Therapeutics has some characteristics of a very speculative penny stock | |
| Enlivex Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (29.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enlivex Therapeutics currently holds about 62.48 M in cash with (23.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enlivex Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of ... |
Enlivex Therapeutics Quarterly Accounts Payable |
|
Enlivex Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Enlivex Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Enlivex Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 21st of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Enlivex Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Enlivex Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-10-30 | 2020-09-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2024-06-14 | 2024-03-31 | -0.25 | -0.22 | 0.03 | 12 | ||
2024-12-02 | 2024-09-30 | -0.16 | -0.12 | 0.04 | 25 | ||
2023-07-31 | 2023-06-30 | -0.46 | -0.4 | 0.06 | 13 | ||
2022-08-22 | 2022-06-30 | -0.45 | -0.54 | -0.09 | 20 | ||
2021-08-06 | 2021-06-30 | -0.26 | -0.17 | 0.09 | 34 | ||
2022-04-29 | 2022-03-31 | -0.28 | -0.45 | -0.17 | 60 | ||
2020-05-18 | 2020-03-31 | -0.24 | -0.07 | 0.17 | 70 |
Know Enlivex Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enlivex Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enlivex Therapeutics backward and forwards among themselves. Enlivex Therapeutics' institutional investor refers to the entity that pools money to purchase Enlivex Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-12-31 | 9.2 K | Signaturefd, Llc | 2024-12-31 | 5 K | Simplex Trading, Llc | 2024-12-31 | 3.4 K | Jpmorgan Chase & Co | 2024-12-31 | 2.6 K | Steward Partners Investment Advisory, Llc | 2024-12-31 | 2.5 K | Bank Of America Corp | 2024-12-31 | 1.1 K | Srs Capital Advisors Inc | 2024-12-31 | 1 K | Bfsg, Llc | 2024-12-31 | 1000 | Activest Wealth Management | 2024-12-31 | 1000 | Armistice Capital, Llc | 2024-12-31 | 2.2 M | Millennium Management Llc | 2024-12-31 | 633.8 K |
Enlivex Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.43 M.Market Cap |
|
Enlivex Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.86) | (0.90) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (0.87) | (0.91) |
Determining Enlivex Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Enlivex Therapeutics is a good buy. For example, gross profit margin measures Enlivex Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Enlivex Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Enlivex Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Enlivex Therapeutics. Check Enlivex Therapeutics' Beneish M Score to see the likelihood of Enlivex Therapeutics' management manipulating its earnings.
Evaluate Enlivex Therapeutics' management efficiency
Enlivex Therapeutics has return on total asset (ROA) of (0.263) % which means that it has lost $0.263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5793) %, meaning that it created substantial loss on money invested by shareholders. Enlivex Therapeutics' management efficiency ratios could be used to measure how well Enlivex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.75 in 2025. Return On Capital Employed is likely to drop to -0.9 in 2025. Non Currrent Assets Other is likely to climb to about 216.1 K in 2025, whereas Total Assets are likely to drop slightly above 30.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.86 | 1.77 | |
| Tangible Book Value Per Share | 1.86 | 1.77 | |
| Enterprise Value Over EBITDA | (1.61) | (1.69) | |
| Price Book Value Ratio | 1.92 | 1.82 | |
| Enterprise Value Multiple | (1.61) | (1.69) | |
| Price Fair Value | 1.92 | 1.82 | |
| Enterprise Value | 45.3 M | 41.9 M |
The decision-making processes within Enlivex Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 1.108 |
Basic technical analysis of Enlivex Stock
As of the 24th of March, Enlivex Therapeutics shows the Mean Deviation of 2.79, standard deviation of 4.32, and Variance of 18.63. Enlivex Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Enlivex Therapeutics standard deviation and potential upside to decide if Enlivex Therapeutics is priced favorably, providing market reflects its regular price of 1.02 per share. Given that Enlivex Therapeutics is a hitting penny stock territory we advise to closely look at its jensen alpha.Enlivex Therapeutics' Outstanding Corporate Bonds
Enlivex Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enlivex Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enlivex bonds can be classified according to their maturity, which is the date when Enlivex Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Enlivex Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Enlivex Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 2.79 | |||
| Coefficient Of Variation | (4,166) | |||
| Standard Deviation | 4.32 | |||
| Variance | 18.63 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | 0.061 | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 31.5 | |||
| Value At Risk | (5.74) | |||
| Potential Upside | 5.98 | |||
| Skewness | 0.5296 | |||
| Kurtosis | 4.88 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 2.79 | |||
| Coefficient Of Variation | (4,166) | |||
| Standard Deviation | 4.32 | |||
| Variance | 18.63 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | 0.061 | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 31.5 | |||
| Value At Risk | (5.74) | |||
| Potential Upside | 5.98 | |||
| Skewness | 0.5296 | |||
| Kurtosis | 4.88 |
Consider Enlivex Therapeutics' intraday indicators
Enlivex Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Enlivex Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 16432.35 | |||
| Daily Balance Of Power | (0.27) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 1.08 | |||
| Day Typical Price | 1.06 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.03) |
Enlivex Stock media impact
Far too much social signal, news, headlines, and media speculation about Enlivex Therapeutics that are available to investors today. That information is available publicly through Enlivex media outlets and privately through word of mouth or via Enlivex internal channels. However, regardless of the origin, that massive amount of Enlivex data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Enlivex Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Enlivex Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Enlivex Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Enlivex Therapeutics alpha.
Enlivex Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Enlivex Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Enlivex Therapeutics Corporate Management
| Veronique AmorBaroukh | Senior Operations | Profile | |
| Shachar CPA | Chief Officer | Profile | |
| Oren Hershkovitz | Chief Officer | Profile | |
| Pr MD | Founder Officer | Profile |
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.